China Resources Boya Bio pharmaceutical Group Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 23.15%

China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has an Asset Resilience Ratio of 23.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥1.95 Billion
≈ $284.73 Million USD Cash + Short-term Investments

Total Assets

CN¥8.41 Billion
≈ $1.23 Billion USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how China Resources Boya Bio pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of China Resources Boya Bio pharmaceutical to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down China Resources Boya Bio pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see China Resources Boya Bio pharmaceutical stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.95 Billion 23.15%
Total Liquid Assets CN¥1.95 Billion 23.15%

Asset Resilience Insights

  • Good Liquidity Position: China Resources Boya Bio pharmaceutical Group Co Ltd maintains a healthy 23.15% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

China Resources Boya Bio pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare China Resources Boya Bio pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Biotechnology 46.79%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 63.47%
Chengdu Kanghua Biological Products
SHE:300841
Biotechnology 1.19%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%

Annual Asset Resilience Ratio for China Resources Boya Bio pharmaceutical Group Co Ltd (2015–2025)

The table below shows the annual Asset Resilience Ratio data for China Resources Boya Bio pharmaceutical Group Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 30.79% CN¥2.66 Billion
≈ $388.79 Million
CN¥8.63 Billion
≈ $1.26 Billion
+4.61pp
2024-12-31 26.18% CN¥2.20 Billion
≈ $321.80 Million
CN¥8.40 Billion
≈ $1.23 Billion
-16.77pp
2023-12-31 42.95% CN¥3.36 Billion
≈ $492.03 Million
CN¥7.83 Billion
≈ $1.15 Billion
+3.19pp
2022-12-31 39.76% CN¥3.19 Billion
≈ $467.37 Million
CN¥8.03 Billion
≈ $1.18 Billion
+4.33pp
2021-12-31 35.42% CN¥2.70 Billion
≈ $395.09 Million
CN¥7.62 Billion
≈ $1.12 Billion
+33.36pp
2016-12-31 2.07% CN¥50.00 Million
≈ $7.32 Million
CN¥2.42 Billion
≈ $354.05 Million
+1.15pp
2015-12-31 0.91% CN¥20.00 Million
≈ $2.93 Million
CN¥2.19 Billion
≈ $320.20 Million
--
pp = percentage points

About China Resources Boya Bio pharmaceutical Group Co Ltd

SHE:300294 China Biotechnology
Market Cap
$1.17 Billion
CN¥8.02 Billion CNY
Market Cap Rank
#8116 Global
#1836 in China
Share Price
CN¥15.91
Change (1 day)
+1.86%
52-Week Range
CN¥14.19 - CN¥27.41
All Time High
CN¥55.20
About

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound b… Read more